TargetMol
![]() |
||
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global small molecule suppliers with over 5000 inhibitors and 80+ compound libraries in stock. TargetMol offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, activator, APIs and natural compounds for laboratory and scientific use. Website : www.targetmol.com |
![SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates](https://www.clinisciences.com/de/upload/thumbs/therapeutic-covid-19-pa7y8c-77b355.jpg)
SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates
Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.
Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.
Ergebnis Ihrer Suche : 25 Produkt(e) gefunden
Grenzen Sie Ihre Suche ein :
RUOCE / IVD
- Biochemicals 25
Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
‹
›